跳至主要内容
临床试验/NCT00557986
NCT00557986已完成不适用

The Effect of Primary Surgical Treatment on Survival in Patients With Metastatic Breast Cancer at Diagnosis

Federation of Breast Diseases Societies8 个研究点 分布在 1 个国家目标入组 281 人开始时间: 2007年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
281
试验地点
8
主要终点
Measure: all cause mortality

研究概览

简要总结

Primary treatments for metastatic breast cancer are chemotherapy and radiation therapy, and surgery is reserved for tumor related complications such as bleeding. Retrospective studies showed that surgical removal of the primary tumor improves survival of patients with metastatic breast cancer at diagnosis. We hypothesis and testing that surgical removal of the primary tumor will lead to an improvement of overall survival

详细描述

This is a randomised, controled clinical trial. Our aim is to observe whether primary surgery improves survival in metastatic breast cancer. Women who have metastatic breast cancer at the initial diagnosis will be included in the study. There will be two study arms: primary surgery and systemic chemotherapy groups.

In the primary surgery group patients will have adjuvant therapies after they had the proper surgery. In the systemic chemotherapy group patients will be followed after their initial therapy and will have surgery only if they have locoregional problems (such as wide necrosis or bleeding, etc). During the follow-up period, patients will be seen in every 6 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • Women with metastatic breast cancer at the initial diagnosis

排除标准

  • Women needs breast surgery at the time of initial diagnosis (such as bleeding, necrosis, etc)
  • who have systemic morbidity that do not allows her to be in the trial,
  • who have synchronous breast cancer at the contralateral breast,
  • who have a previous cancer history or another primary cancer history and metastasis at the past,
  • who have palpable lymph node/nodes at the contralateral axilla,
  • who do not agree to participate the trial

结局指标

主要结局

Measure: all cause mortality

时间窗: 5 years

次要结局

  • Quality of life(5 year)
  • mordities(5 years)

研究者

发起方
Federation of Breast Diseases Societies
申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验